Advocating for Hodgkin Lymphoma Care: Jenny's Immunotherapy Story

Jenny was still in college when she learned she had advanced Hodgkin lymphoma. #CIM17 #PatientStories

Her mother researched immunotherapy clinical trial options and helped Jenny become her own patient advocate. She enrolled in a trial testing a combination of the anti-PD-1 checkpoint inhibitor nivolumab (Opdivo) along with the antibody-drug conjugate brentuximab vedotin (Adcentris). www.cancerresearch.org/patients

This video is presented as part of the Cancer Research Institute 5th Annual Cancer Immunotherapy Month awareness campaign this June 2017. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. http://www.cancerresearch.org/june

Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org